Status:

RECRUITING

Neurofibromatosis Type 1 Tumor Early Detection Study

Lead Sponsor:

David Miller

Conditions:

Neurofibromatosis Type 1

Neurofibromatosis 1

Eligibility:

All Genders

18+ years

Brief Summary

The goal of this observational study is to determine if a liquid biopsy (i.e. blood test) is an effective clinical tool for monitoring the development of malignant peripheral nerve sheath tumor (MPNST...

Eligibility Criteria

Inclusion

  • 18 years and older (adults only)
  • Neurofibromatosis Type 1 (NF1) diagnosis (2021 Revised Diagnostic Criteria, PMID: 34012067)
  • History of plexiform neurofibroma (PN)
  • Able to read and understand English or Spanish
  • Live in the USA

Exclusion

  • Are children (younger than 18 years old)
  • Do not have NF1
  • Have no evidence of PN
  • Are not able to read and understand English or Spanish

Key Trial Info

Start Date :

August 7 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2030

Estimated Enrollment :

1000 Patients enrolled

Trial Details

Trial ID

NCT06515860

Start Date

August 7 2024

End Date

July 1 2030

Last Update

January 9 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Boston Children's Hospital

Boston, Massachusetts, United States, 02115